Your weekly update is here with new data on switching to the oral Wegovy pill, plus steady ways to protect muscle and stay safe on GLP-1s. # Weekly Briefing: Oct 5, 2026 **TL;DR:** Switching from injectable to oral Wegovy pill showed 4.1% weight loss in 3 months, muscle protection stays protein + resistance, and FDA flagged 1,700+ reports on compounded versions. ## 💊 GLP1 News ### New research & approvals People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026. In the OCTANE study, adults who switched from an injectable GLP-1 to once-daily oral semaglutide and stayed on for 3 months lost an average 4.1% or 8.8 lbs from a 221.6 lb start. Pipeline watch: Novo licensed HRS-1596, an early-stage oral dual GLP-1/GIP candidate designed for once-weekly dosing now in Phase 1 in China, and Boehringer's survodutide dual agonist data showing up to 13.1% was presented at EASD Oct 1. Foundayo (orforglipron) was approved April 1, 2026 for chronic weight management. ### Weight management tips Preserve lean mass from the start: Aim for adequate protein, commonly around 1.2–1.6 g/kg/day and spread it across meals rather than one large serving. Perform progressive resistance training at least 2 days per week. Why it matters: studies show 25-40% of weight lost on GLP-1 therapy can come from lean tissue. Practical: 25-30g protein per meal, 2-3 strength days, 10-min walk after eating. ### Side effects & safety FDA warning Sep 8: FDA warns on compounded GLP-1s amid 1,700+ safety reports as adverse events for compounded semaglutide and tirzepatide surpassed 1,700. Stick to FDA-approved prescriptions and report side effects to MedWatch. FDA labeling also warns about acute kidney injury associated with volume depletion in the setting of GI reactions — stay hydrated. Earlier this year, federal regulators said Wegovy and Zepbound do not increase risk of suicidal thoughts and asked makers to remove those warnings.